Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility
Source: SeekingAlpha
2025-11-19 14:43:12 ET
Investment Overview
The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at $23 per share, which translates to a market cap valuation of ~$1.4bn....
Read the full article on Seeking Alpha
For further details see:
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
2.51% G/L:
$28.21 Last:
38,789 Volume:
$27.71 Open:
AGIO Latest News
March 11, 2026 09:00:00 am
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
March 10, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
